Summit Therapeutics plc Notice Of Results
10 Ottobre 2019 - 03:30PM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Summit Therapeutics to Report Financial Results for the Second Quarter
and Half Year Ended 31 July 2019 on 11 October 2019
Oxford, UK, and Cambridge, MA, US, 10 October 2019 -- Summit
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism
antibiotic innovation, will announce its financial results for the
second quarter and half year ended 31 July 2019 on 11 October 2019.
Summit will host a conference call the same day at 1:00pm BST / 8:00am
EDT. Conference call information will be included in the second quarter
and half year results press release, and a replay of the call will also
be available through the Company's website,
https://www.globenewswire.com/Tracker?data=ydiA0X52xo6WqJeZX1Q2Y51kX4rSSJdH9qOMPspThtwGJDkn3f4xV_NEC2_IHHyDReuusJVwUD9K_HHvH77miUUIUPyRwlUzlRX9rTAlasQ=
www.summitplc.com.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae
and are using our proprietary Discuva Platform to expand our pipeline.
For more information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6652
mailto:summit@mslgroup.com
Erin Anthoine summit@mslgroup.com
------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina Virji mailto:summit@consilium-comms.
com
summit@consilium-comms.com
------------------------------
Lindsey Neville
-END-
(END) Dow Jones Newswires
October 10, 2019 09:30 ET (13:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Summit Therapeutics (LSE:SUMM)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Summit Therapeutics (LSE:SUMM)
Storico
Da Mar 2023 a Mar 2024
Notizie in Tempo Reale relative a Summit Therapeutics Plc (Borsa di Londra): 0 articoli recenti
Più Summit Therapeutics Plc Articoli Notizie